Handelsavisen
prelaunch
Companies Healthcare SIGA.KL
SI
SIGA.KL Bursa Malaysia Pharmaceuticals

Signature Alliance Group Bhd

$0,72
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
2,74 %
Op margin
13,3 %
ROE
18,4 %
Net margin
9,1 %
Debt / equity
0,19
Beta
52w range
Volume
13
Day range
Prev close
$4,76
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Signature Alliance Group Bhd provides business support services, primarily generating revenue through industrial and commercial service offerings.

Business. Signature Alliance Group Bhd (SIGA.KL) is a business support services company operating within the Industrial & Commercial Services sector. The firm is headquartered in Malaysia and is primarily listed on Bursa Malaysia. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %
SectorHealth Care
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
Arrowstreet Capital, Limited Partnership
largest disclosed fund holder
Profitability
18,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning SIGA.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to SIGA.KL. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Signature Alliance Group Bhd (SIGA.KL) is a business support services company operating within the Industrial & Commercial Services sector. The firm is headquartered in Malaysia and is primarily listed on Bursa Malaysia. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification99 %
    SectorHealth Care
    Industry groupPharmaceuticals
    AI synthesis
    GENERATED

    Signature Alliance Group Bhd maintains a relatively strong liquidity position, with a liquidity FPT of 0.19, indicating a low debt-to-equity ratio of 0.19. The company's return on equity (ROE) of 18.38% and return on assets (ROA) of 10.15% suggest robust profitability relative to its equity and asset base.

    The company's profitability metrics align with the preferred industry metrics for Business Support Services, which emphasize ROE and ROA as key indicators of performance. Its ROE of 18.38% is well above the typical median for the sector, indicating strong returns for shareholders.

    The company's revenue is concentrated in a single disclosed segment, with no geographic breakdown provided in the available data. This lack of diversification may expose the company to regional economic fluctuations, though the extent of geographic risk cannot be assessed without further data.

    The company's growth trajectory is modest, with no significant revenue growth or decline reported in the latest financial period. The outlook for the current fiscal year suggests a stable revenue trend, with no major directional shifts expected in the near term.

    The company faces moderate liquidity risk, as noted in the risk assessment, with a liquidity rating of medium. The risk assessment also highlights a key flag: net cash is negative after subtracting total debt, which could impact the company's ability to meet short-term obligations. However, the dilution risk is assessed as low, and no significant adjustments have been applied to the valuation metrics.

    Recent filings and transcripts do not indicate any material events or strategic shifts that would significantly alter the company's financial position or operational strategy. The company appears to be operating within a stable and predictable framework.

    Key takeaways
    • Signature Alliance Group Bhd demonstrates strong profitability with a ROE of 18.38% and ROA of 10.15%.
    • The company maintains a low debt-to-equity ratio of 0.19, indicating a conservative capital structure.
    • Revenue is concentrated in a single segment, with no geographic diversification disclosed.
    • The company's liquidity risk is moderate, with a key flag indicating negative net cash after debt.
    • No significant dilution risk is present, and the company's growth trajectory is stable.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $0,72
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $238.4M
    Net cash
    -$45.6M
    Current ratio
    Debt / equity
    0.2
    ROA
    10.2%
    ROE
    18.4%
    Cash conversion
    13.0%
    CapEx / revenue
    -0.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryPharmaceuticals695,2B node revenueJNJ 13,6%LLY 9,4%MRK 9,3%PFE 9,0%ABBV 8,8%AZN 8,4%BMY 6,9%GSK 6,2%Other 28,3%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)SIGA 0,0% · rank #43 of 68

    Business relationships

    Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures
    Suppliers1
    Albemarle CorpALB.OSupplier90%Source ↗

    Supply chain

    Vendors → SIGA ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSSIGASIGASignature Alliance Group Bhd1 entityAlbemarle CorpDiversified Specialty ChUS
    1 mention in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    Peer comparison8 peers · vs SIGA · multiples and returns
    JN
    JNJ
    Johnson & Johnson
    $254,43
    622,1B USD
    P/E
    23,5x
    -6,2 vs self
    Div yield
    2,0 %
    -13,7 vs self
    ROE
    33,0 %
    +26,8 vs self
    LL
    LLY
    ELI LILLY AND COMPANY
    $1 124,04
    1,01T USD
    P/E
    52,0x
    +22,3 vs self
    Div yield
    0,5 %
    -15,1 vs self
    ROE
    66,2 %
    +59,9 vs self
    MR
    MRK
    MERCK & CO., INC.
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    PF
    PFE
    Pfizer Inc
    $25,05
    143,6B USD
    P/E
    18,2x
    -11,5 vs self
    Div yield
    6,9 %
    -8,8 vs self
    ROE
    8,6 %
    +2,4 vs self
    AB
    ABBV
    Abbvie Inc
    $245,10
    434,8B USD
    P/E
    110,6x
    +80,9 vs self
    Div yield
    2,5 %
    -13,1 vs self
    ROE
    -63,5 %
    -69,7 vs self
    AZ
    AZN
    AZN.L
    $157,59
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    BM
    BMY
    Bristol-myers Squibb Co
    $65,60
    134,3B USD
    P/E
    17,7x
    -12,0 vs self
    Div yield
    4,1 %
    -11,6 vs self
    ROE
    31,6 %
    +25,4 vs self
    GS
    GSK
    Gsk Plc-spon Adr
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,09
    Predicted surprise
    0,00
    Beat probability
    45 %
    Analysts
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-16 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin13,3 %Above median
    Net Margin9,2 %Above median
    ROE18,4 %Above P75
    Capex / Rev-0,6 %Above P75
    D/E0,19Below median
    Cash Conv0,13Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 328 768 sh13 exercises · 11 grants11 insiders
    • DURNAN JAYMIE ADirector · Restricted Stock Units → Common Stock, par value $.0001 per shareAcquired 34 169grant · 2026-06-09
    • Marshall Joseph W IIIDirector · Restricted Stock Units → Common Stock, par value $.0001 per shareDisposed 24 116exercise · 2026-06-09
    • Marshall Joseph W IIIDirector · Restricted Stock Units → Common Stock, par value $.0001 per shareAcquired 34 169grant · 2026-06-09
    • KEANE JOHN MDirector · Restricted Stock Units → Common Stock, par value $.0001 per shareDisposed 24 116exercise · 2026-06-09
    • KEANE JOHN MDirector · Restricted Stock Units → Common Stock, par value $.0001 per shareAcquired 34 169grant · 2026-06-09
    • Ford Harold Eugene Jr.Director · Restricted Stock Units → Common Stock, par value $.0001 per shareDisposed 24 116exercise · 2026-06-09
    • Ford Harold Eugene Jr.Director · Restricted Stock Units → Common Stock, par value $.0001 per shareAcquired 34 169grant · 2026-06-09
    • Phillips Holly L.Director · Restricted Stock Units → Common Stock, par value $.0001 per shareDisposed 24 116exercise · 2026-06-09
    • Phillips Holly L.Director · Restricted Stock Units → Common Stock, par value $.0001 per shareAcquired 34 169grant · 2026-06-09
    • Nemirovsky JulianDirector · Restricted Stock Units → Common Stock, par value $.0001 per shareDisposed 24 116exercise · 2026-06-09
    • Nemirovsky JulianDirector · Restricted Stock Units → Common Stock, par value $.0001 per shareAcquired 34 169grant · 2026-06-09
    • DURNAN JAYMIE ADirector · Restricted Stock Units → Common Stock, par value $.0001 per shareDisposed 24 116exercise · 2026-06-09
    • Nabel Gary J.Director · Restricted Stock Unites → Common Stock, par value $.0001 per shareDisposed 24 116exercise · 2026-06-09
    • Nabel Gary J.Director · Restricted Stock Units → Common Stock, par value $.0001 per shareAcquired 34 169grant · 2026-06-09
    • Miller Larry R.General Counsel · Restricted Stock Units → Common Stock, par value $.0001 per shareDisposed 6 920exercise · 2026-03-25
    • Luckshire Daniel JExecutive VP & CFO · Restricted Stock Units → Common Stock, par value $.0001 per shareDisposed 11 503exercise · 2026-03-13
    • Luckshire Daniel JExecutive VP & CFO · Restricted Stock Units → Common Stock, par value $.0001 per shareAcquired 55 228grant · 2026-03-13
    • Hruby Dennis EEVP & Chief Scientific Officer · Restricted Stock Units → Common Stock, par value $.0001 per shareDisposed 11 445exercise · 2026-03-13
    • Hruby Dennis EEVP & Chief Scientific Officer · Restricted Stock Units → Common Stock, par value $.0001 per shareAcquired 54 942grant · 2026-03-13
    • Miller Larry R.General Counsel · Restricted Stock Units → Common Stock, par value $.0001 per shareDisposed 21 261exercise · 2026-03-13
    • Miller Larry R.General Counsel · Restricted Stock Units → Common Stock, par value $.0001 per shareAcquired 68 060grant · 2026-03-13
    • Nguyen DiemDirector, Chief Executive Officer · Restricted Stock Units → Common Stock, par value $.0001 per shareDisposed 85 045exercise · 2026-03-13
    • Nguyen DiemDirector, Chief Executive Officer · Restricted Stock Units → Common Stock, par value $.0001 per shareAcquired 272 243grant · 2026-03-13
    • Nguyen DiemDirector, Chief Executive Officer · Restricted Stock Units → Common Stock, par value $.0001 per shareDisposed 55 902exercise · 2026-01-27

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Signature Alliance Group Bhd Market data — financials · 2026-05-29

    Ownership & reference

    Top holders

    • Arrowstreet Capital, Limited PartnershipInvestment Managers · as of 2026-03-310,00 %$8M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$7M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$14M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$7M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$30M
    • First Trust Advisors L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$1M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$3M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$7M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$1M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$1M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$17M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$1M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$5M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$1M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Mixed / flat0 buys · 0 sellsnet $011 insiders · last 365d
    • Ford Harold Eugene Jr.Director · Common Stock, par value $.0001 per shareOther 7 235 @ $4,39$32K · 2026-06-09
    • Phillips Holly L.Director · Common Stock, par value $.0001 per shareOther 24 116 · 2026-06-09
    • Phillips Holly L.Director · Common Stock, par value $.0001 per shareOther 7 235 @ $4,39$32K · 2026-06-09
    • Nemirovsky JulianDirector · Common Stock, par value $.0001 per shareOther 24 116 · 2026-06-09
    • Nemirovsky JulianDirector · Common Stock, par value $.0001 per shareOther 7 235 @ $4,39$32K · 2026-06-09
    • Marshall Joseph W IIIDirector · Common Stock, par value $.0001 per shareOther 24 116 · 2026-06-09
    • Marshall Joseph W IIIDirector · Common Stock, par value $.0001 per shareOther 7 235 @ $4,39$32K · 2026-06-09
    • KEANE JOHN MDirector · Common Stock, par value $.0001 per shareOther 24 116 · 2026-06-09
    • KEANE JOHN MDirector · Common Stock, par value $.0001 per shareOther 7 235 @ $4,39$32K · 2026-06-09
    • Ford Harold Eugene Jr.Director · Common Stock, par value $.0001 per shareOther 24 116 · 2026-06-09
    • DURNAN JAYMIE ADirector · Common Stock, par value $.0001 per shareOther 24 116 · 2026-06-09
    • DURNAN JAYMIE ADirector · Common Stock, par value $.0001 per shareOther 7 235 @ $4,39$32K · 2026-06-09
    • Nabel Gary J.Director · Common Stock, par value $.0001 per shareOther 24 116 · 2026-06-09
    • Nabel Gary J.Director · Common Stock, par value $.0001 per shareOther 7 235 @ $4,39$32K · 2026-06-09
    • Miller Larry R.General Counsel · Common Stock, par value $.0001 per shareOther 3 526 @ $4,99$18K · 2026-03-25
    • Miller Larry R.General Counsel · Common Stock, par value $.0001 per shareOther 6 920 · 2026-03-25
    • Miller Larry R.General Counsel · Common Stock, par value $.0001 per shareOther 21 261 · 2026-03-13
    • Nguyen DiemDirector, Chief Executive Officer · Common Stock, par value $.0001 per shareOther 47 029 @ $5,26$247K · 2026-03-13
    • Hruby Dennis EEVP & Chief Scientific Officer · Common Stock, par value $.0001 per shareOther 3 955 @ $5,26$21K · 2026-03-13
    • Miller Larry R.General Counsel · Common Stock, par value $.0001 per shareOther 11 187 @ $5,26$59K · 2026-03-13
    • Luckshire Daniel JExecutive VP & CFO · Common Stock, par value $.0001 per shareOther 11 503 · 2026-03-13
    • Luckshire Daniel JExecutive VP & CFO · Common Stock, par value $.0001 per shareOther 6 074 @ $5,26$32K · 2026-03-13
    • Nguyen DiemDirector, Chief Executive Officer · Common Stock, par value $.0001 per shareOther 85 045 · 2026-03-13
    • Hruby Dennis EEVP & Chief Scientific Officer · Common Stock, par value $.0001 per shareOther 11 445 · 2026-03-13
    • Nguyen DiemDirector, Chief Executive Officer · Common Stock, par value $.0001 per shareOther 55 902 · 2026-01-27

    Short positioning

    3.9Mshares short+13.5% vs prior
    6.89days to cover
    48.2%short of daily vol
    27fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    SIGA.KLCanonical
    Bursa Malaysia · USD

    Intel & risk

    PredictorBeat prob45 %Surprise0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    SIGAALB.OPharmaceutical
    This companySectorSuppliers

    Evidence & claims

    From filings & derived data
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -10.2%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -10.8%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -66.1%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -0.3%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 62.1%Derived (calculated)
    • Net margin (FY 2025-12-31): 24.6%Derived (calculated)
    • Return on equity (FY 2025-12-31): 11.7%Derived (calculated)
    • Return on assets (FY 2025-12-31): 10.6%Derived (calculated)
    • Current ratio (FY 2025-12-31): 11.83xDerived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -60.7%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -7.9%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -27.6%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -5.1%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -61.0%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -60.2%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): -31.8%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.10xDerived (calculated)
    • Operating cash flow (annual): USD 43.47MSEC XBRL filing
    • R&D expense (annual): USD 19.96MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES 0SEC XBRL filing
    • Operating income (annual): USD 23.7MSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES 0SEC XBRL filing
    • Current assets (annual): USD 212.86MSEC XBRL filing
    • Shareholders' equity (annual): USD 198.82MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-10FILING8-K filing →
    2026-06-09 00:00 UTCINSIDER28 insider transactions — 2026-06 · net sell $222k 14 derivative
    2026-06-09INSIDERFord Harold Eugene Jr. transacted 7.2k sh Common Stock, par value $.0001 per share — Director ~$32k
    2026-06-09INSIDERPhillips Holly L. transacted 24.1k sh Common Stock, par value $.0001 per share — Director
    2026-06-09INSIDERPhillips Holly L. transacted 7.2k sh Common Stock, par value $.0001 per share — Director ~$32k
    2026-06-09INSIDERNemirovsky Julian transacted 24.1k sh Common Stock, par value $.0001 per share — Director
    2026-06-09INSIDERNemirovsky Julian transacted 7.2k sh Common Stock, par value $.0001 per share — Director ~$32k
    2026-06-09INSIDERMarshall Joseph W III transacted 24.1k sh Common Stock, par value $.0001 per share — Director
    2026-06-09INSIDERMarshall Joseph W III transacted 7.2k sh Common Stock, par value $.0001 per share — Director ~$32k
    2026-06-09INSIDERKEANE JOHN M transacted 24.1k sh Common Stock, par value $.0001 per share — Director
    2026-06-09INSIDERKEANE JOHN M transacted 7.2k sh Common Stock, par value $.0001 per share — Director ~$32k
    2026-06-09INSIDERFord Harold Eugene Jr. transacted 24.1k sh Common Stock, par value $.0001 per share — Director
    2026-06-09INSIDERDURNAN JAYMIE A transacted 24.1k sh Common Stock, par value $.0001 per share — Director
    2026-06-09INSIDERDURNAN JAYMIE A transacted 7.2k sh Common Stock, par value $.0001 per share — Director ~$32k
    2026-06-09INSIDERNabel Gary J. transacted 24.1k sh Common Stock, par value $.0001 per share — Director
    2026-06-09INSIDERNabel Gary J. transacted 7.2k sh Common Stock, par value $.0001 per share — Director ~$32k
    2026-06-09INSIDERFord Harold Eugene Jr. disposed of 24.1k sh Restricted Stock Units — Director
    2026-06-09INSIDERFord Harold Eugene Jr. acquired 34.2k sh Restricted Stock Units — Director
    2026-06-09INSIDERPhillips Holly L. disposed of 24.1k sh Restricted Stock Units — Director
    2026-06-09INSIDERPhillips Holly L. acquired 34.2k sh Restricted Stock Units — Director
    2026-06-09INSIDERNemirovsky Julian disposed of 24.1k sh Restricted Stock Units — Director
    2026-06-09INSIDERNemirovsky Julian acquired 34.2k sh Restricted Stock Units — Director
    2026-06-09INSIDERDURNAN JAYMIE A disposed of 24.1k sh Restricted Stock Units — Director
    2026-06-09INSIDERKEANE JOHN M disposed of 24.1k sh Restricted Stock Units — Director
    2026-06-09INSIDERNabel Gary J. disposed of 24.1k sh Restricted Stock Unites — Director
    2026-06-09INSIDERNabel Gary J. acquired 34.2k sh Restricted Stock Units — Director
    2026-06-09INSIDERDURNAN JAYMIE A acquired 34.2k sh Restricted Stock Units — Director
    2026-06-09INSIDERKEANE JOHN M acquired 34.2k sh Restricted Stock Units — Director
    2026-06-09INSIDERMarshall Joseph W III acquired 34.2k sh Restricted Stock Units — Director
    2026-06-09INSIDERMarshall Joseph W III disposed of 24.1k sh Restricted Stock Units — Director
    2026-05-07FILINGFORM 10-Q →
    2026-05-07FILING8-K filing →
    2026-04-28FILINGDEF 14A filing →
    2026-03-26FILING8-K filing →
    2026-03-25 00:00 UTCINSIDER19 insider transactions — 2026-03 · net sell $377k 9 derivative
    2026-03-25INSIDERMiller Larry R. transacted 3.5k sh Common Stock, par value $.0001 per share — General Counsel ~$18k
    2026-03-25INSIDERMiller Larry R. transacted 6.9k sh Common Stock, par value $.0001 per share — General Counsel
    2026-03-25INSIDERMiller Larry R. disposed of 6.9k sh Restricted Stock Units — General Counsel
    Showing the 40 most recent of 61 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage